Evidence map›Paper›PMID 42005916›Full record

ArticleEClinicalMedicine2026

Nitrous oxide for late-life depression with inadequate antidepressant response: a randomised controlled trial.

Antony Salamé, Samuel Bulteau, Gabriel Robert, Anaïs Vandevelde, Valérie Gissot, Marie-Sara Agier, Quentin Gallet, Jacques-Alexis Nkodo, Victoire Leroy, Paul Brunault and 8 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Antony SalaméCHU de Tours, Tours, France.
Samuel BulteauCHU de Nantes, Addictology and Liaison Psychiatry Department, 44000, Nantes, France.
Gabriel RobertEmpenn U1228, INSERM, INRIA, Université de Rennes, UMR CNRS 6074 IRISA, Campus de Beaulieu, 35042, Rennes, Cedex, France.
Anaïs VandeveldeCHU de Tours, Tours, France.
Valérie GissotCHU de Tours, Tours, France.
Marie-Sara AgierCHU de Tours, Tours, France.
Quentin GalletCHU de Angers, Angers, France.
Jacques-Alexis NkodoCHU de Tours, Tours, France.
Victoire LeroyCHU de Tours, Tours, France.
Paul BrunaultCHU de Tours, Tours, France.
Hélène BourgoinCHU de Tours, Tours, France.
Nicolas ArlicotCHU de Tours, Tours, France.
Fabien EspitalierCHU de Tours, Tours, France.
Amélie Le GougeCHU de Tours, Tours, France.
Wissam El-HageCHU de Tours, Tours, France.
Vincent CamusCHU de Tours, Tours, France.
Pierre PoupinCHU de Tours, Tours, France.
Thomas DesmidtCHU de Tours, Tours, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Late-life depression with inadequate antidepressant response is a pressing clinical issue with limited proven therapies. Nitrous oxide (N Methods: We conducted a double-blind, randomised, placebo-controlled, single-dose trial (November 2021-December 2024) in three old-age psychiatry departments at French university hospitals. Eligible participants were aged 60-90 years with a current major depressive episode, a Montgomery-Åsberg Depression Rating Scale (MADRS) score >20 and documented non-response to ≥1 adequate antidepressant trial. Participants were randomly assigned (1:1) to a single 60-min inhalation of either 50% N Findings: Among the 60 participants enrolled in the study, those who received N Interpretation: While further studies are needed to confirm its long-term efficacy and safety, our findings suggest that N Funding: This study was supported by a grant from the French Ministry of Health and Prevention.

Indexed as

Inadequate antidepressant responseLate-life depressionNitrous oxide

Identifiers

PMID42005916
PMCPMC13084366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.